Edit
EpiFrontier Therapeutics, Inc.
https://epifrontiertx.com/Last activity: 18.07.2026
Probably Closed
EpiFrontier is a biotech company advancing oral therapies for beta-globin disorders, powered by epigenetic drug discovery science from RIKEN and Tokyo University of Pharmacy and Life Sciences.
Our lead candidate, EPF-001, is an oral, selective G9a inhibitor that raises fetal hemoglobin to address the root cause of sickle cell disease and beta-thalassemia.
Boosting fetal hemoglobin is a clinically validated way to modify these diseases, and in preclinical studies EPF-001 has shown potentially best-in-class fetal hemoglobin induction with a clean safety and pharmacokinetic profile. Where today's options fall short—inconsistent efficacy, or the cost and complexity of cell and gene therapies—EPF-001 is designed to do better, with the goal of bringing effective treatment within reach of patients everywhere.
Our lead candidate, EPF-001, is an oral, selective G9a inhibitor that raises fetal hemoglobin to address the root cause of sickle cell disease and beta-thalassemia.
Boosting fetal hemoglobin is a clinically validated way to modify these diseases, and in preclinical studies EPF-001 has shown potentially best-in-class fetal hemoglobin induction with a clean safety and pharmacokinetic profile. Where today's options fall short—inconsistent efficacy, or the cost and complexity of cell and gene therapies—EPF-001 is designed to do better, with the goal of bringing effective treatment within reach of patients everywhere.
Investors 1
| Date | Name | Website |
| 18.07.2026 | The Univer... | ut-ec.co.j... |
Mentions in press and media 1
| Date | Title | Description |
| 24.03.2026 | EpiFrontier Therapeutics Raises up to $32M Grant From Japan Agency for Medical Research and Development (AMED) | EpiFrontier Therapeutics, Inc., a Pennington, NJ-based biotechnology company developing therapies for beta globin disorders, raised up to $32M in non-dilutive funding from the Japan Agency for Medical Research and Development (AMED). The co... |